Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 685509 versus placebo in systemic sclerosis
NL-OMON58776Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in systemic sclerosis (SSc) comparing BI 685509 with Placebo (2 arms). Primary endpoint: Annual rate of decline in forced vital capacity. Started Jan 2023; status: completed.
02
Drugs
avenciguat
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON58776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58776.